Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Formisano, Luigi, Lu, Yao, Servetto, Alberto, Hanker, Ariella B., Jansen, Valerie M., Bauer, Joshua A., Sudhan, Dhivya R., Guerrero-Zotano, Angel L., Croessmann, Sarah, Guo, Yan, Ericsson, Paula Gonzalez, Lee, Kyung-min, Nixon, Mellissa J., Schwarz, Luis J., Sanders, Melinda E., Dugger, Teresa C., Cruz, Marcelo Rocha, Behdad, Amir, Cristofanilli, Massimo, Bardia, Aditya, O’Shaughnessy, Joyce, Nagy, Rebecca J., Lanman, Richard B., Solovieff, Nadia, He, Wei, Miller, Michelle, Su, Fei, Shyr, Yu, Mayer, Ingrid A., Balko, Justin M., Arteaga, Carlos L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435685/
https://www.ncbi.nlm.nih.gov/pubmed/30914635
http://dx.doi.org/10.1038/s41467-019-09068-2

Ejemplares similares

Ejemplares similares